摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-Cyclobutylpropan-1-ol | 1380582-94-4

中文名称
——
中文别名
——
英文名称
1-Cyclobutylpropan-1-ol
英文别名
——
1-Cyclobutylpropan-1-ol化学式
CAS
1380582-94-4
化学式
C7H14O
mdl
——
分子量
114.19
InChiKey
NPFXICARYVUUJI-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.8
  • 重原子数:
    8
  • 可旋转键数:
    2
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    1.0
  • 拓扑面积:
    20.2
  • 氢给体数:
    1
  • 氢受体数:
    1

文献信息

  • [EN] SMALL LIPOPEPTIDOMIMETIC INHIBITORS OF GHRELIN O-ACYL TRANSFERASE<br/>[FR] PETITS INHIBITEURS LIPOPEPTIDOMIMÉTIQUES DE LA GHRÉLINE O-ACYL TRANSFÉRASE
    申请人:UNIV CALIFORNIA
    公开号:WO2016044467A1
    公开(公告)日:2016-03-24
    Compositions and methods are disclosed that relate to small molecule lipopeptidomimetic inhibitors of mammalian ghrelin O-acyl transferase (GOAT). Compounds of general Formula (I) and substructures thereof, i.e., Formulae (II), (IIa), (IIa1), (IIa2), (IIb), (IIb1), (IIb2), (IIc) and (III), are shown to exhibit potent inhibition of the octanoylation of ghrelin peptide, where the resulting non-octanoylated (des-acyl) form of ghrelin lacks GHSr ligand activity that is associated with weight gain and insulin resistance. These and related embodiments will find uses for treating subjects known to have, or suspected of being at risk for having, a condition that would benefit from a decreased level of acylated ghrelin peptide, such as type II diabetes, impaired glucose tolerance, insulin resistance, Prader-Willi syndrome (PWS) and obesity.
    公开了与哺乳动物生长激素释放肽O-酰基转移酶(GOAT)的小分子脂肽类似物抑制剂有关的组合物和方法。通式(I)及其亚结构,即,通式(II)、(IIa)、(IIa1)、(IIa2)、(IIb)、(IIb1)、(IIb2)、(IIc)和(III)的化合物显示出对生长激素释放肽的辛酰化反应的强大抑制作用,其中产生的非辛酰化(脱酰基)形式的生长激素释放肽缺乏与体重增加和胰岛素抵抗相关的GHSr配体活性。这些和相关实施例可用于治疗已知或怀疑有患有可能从降低酰化生长激素释放肽平中受益的病症的患者,例如II型糖尿病、葡萄糖耐量受损、胰岛素抵抗、普拉德-威利综合症(PWS)和肥胖。
  • PREPARATION OF 3-AMINO-3-(CYCLOBUTYLMETHYL)-2-(HYDROXY)-PROPIONAMIDE HYDROCHLORIDE
    申请人:Park Jeonghan
    公开号:US20100113821A1
    公开(公告)日:2010-05-06
    Disclosed is a process for preparing 3-(amino)-3-cyclobutylmethyl-2-hydroxy-propionamide hydrochloride, an intermediate useful in the preparation of the HCV protease inhibitor (1R,5S)—N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3-[2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide.
    本发明公开了一种制备3-(基)-3-环丁基甲基-2-羟基-丙酰胺盐酸盐的方法,该中间体在制备HCV蛋白酶抑制剂(1R,5S)-N-[3-基-1-(环丁基甲基)-2,3-二氧代丙基]-3-[2(S)-[[[(1,1-二甲基乙基)基]羰基]基]-3,3-二甲基-1-氧代丁基]-6,6-二甲基-3-氮杂双环[3.1.0]己烷-2(S)-羧酰胺中有用。
  • Pyrrolopyridazinone Compound
    申请人:Hagihara Masahiko
    公开号:US20090036453A1
    公开(公告)日:2009-02-05
    The present invention discloses a pyrrolopyridazinone compound represented by the formula (1): wherein R 1 represents C 1 -C 2 alkyl group or halogeno C 1 -C 2 alkyl group, R 2 repersents C 3 -C 5 cycloalkyl group, (C 3 -C 5 cycloalkyl)C 1 -C 2 alkyl group or C 1 -C 3 alkyl group, R 3 represents hydrogen atom, or methylene group or cis-vinylene group for forming substituted oxygen-containing hetero ring in combination with group —O—R 2 , R 4 represents hydrogen atom, halogen atom, C 1 -C 8 alkyl group, C 2 -C 6 alkenyl group, C 2 -C 6 alkynyl group, hydroxy C 3 -C 6 alkenyl group, hydroxy C 3 -C 6 alkynyl group, C 1 -C 6 alkyl group substituted by substituent(s) selected from Substituent group (a), C 3 -C 6 cycloalkyl group which may be substituted by substituent(s) selected from Substituent group (b), “C 1 -C 3 alkyl group which is substituted by C 3 -C 6 cycloalkyl group which may be substituted by substituent(s) selected from Substituent group (b), and which may be substituted by a hydroxy group”, an aromatic ring group or heteroaromatic ring group each of which may be substituted by a substituent(s) selected from Substituent group (c) or “C 1 -C 2 alkyl group which is substituted by aromatic ring group or heteroaromatic ring group each of which may be substituted by group(s) selected from Substituent group (c), and which may be substituted by a hydroxy group”, Substituent group (a) represents a halogen atom, hydroxy group, cyano group, carboxy group, C 1 -C 5 alkoxy group, halogeno C 1 -C 4 alkoxy group, C 3 -C 6 cycloalkoxy group, (C 3 -C 6 cycloalkyl)C 1 -C 2 alkoxy group, C 1 -C 4 alkoxycarbonyl group, C 2 -C 4 alkanoyl group, C 2 -C 4 alkanoyloxy group or C 1 -C 4 alkyl-substituted amino group, Substituent group (b) represents a hydroxy group or a halogen atom, Substituent group (c) represents a halogen atom, a hydroxy group, a cyano group, a nitro group, a carboxy group, C 1 -C 5 alkoxy group, C 1 -C 4 alkoxycarbonyl group, C 2 -C 4 alkanoyloxy group, C 1 -C 4 alkyl-substituted amino group or a C 1 -C 4 alkyl group which may be substituted by a substituent(s) selected from the group consisting of (a halogen atom, a hydroxy group and a carboxy group), or a pharmaceutically acceptable salt thereof.
    本发明公开了一种由式(1)表示的吡咯吡啶二酮化合物:其中,R1代表C1-C2烷基或卤代C1-C2烷基,R2代表C3-C5环烷基、(C3-C5环烷基)C1-C2烷基或C1-C3烷基,R3代表氢原子,或与基团-O-R2结合形成取代含氧杂环的亚甲基或顺式乙烯基,R4代表氢原子、卤素原子、C1-C8烷基、C2-C6烯基、C2-C6炔基、羟基C3-C6烯基、羟基C3-C6炔基、由从取代基团(a)中选择的取代基团取代的C1-C6烷基,可由从取代基团(b)中选择的取代基团取代的C3-C6环烷基,可由从取代基团(b)中选择的取代基团取代的C1-C3烷基,且可由羟基取代,芳香环基或杂芳香环基,每个都可由从取代基团(c)中选择的取代基团取代或由取代基团(c)选择的基团取代的C1-C2烷基,且可由羟基取代,取代基团(a)表示卤素原子、羟基、基、羧基、C1-C5烷氧基、卤代C1-C4烷氧基、C3-C6环烷氧基、(C3-C6环烷基)C1-C2烷氧基、C1-C4烷氧羰基、C2-C4酰基、C2-C4酰氧基或C1-C4烷基取代的基基团,取代基团(b)表示羟基或卤素原子,取代基团(c)表示卤素原子、羟基、基、硝基、羧基、C1-C5烷氧基、C1-C4烷氧羰基、C2-C4酰氧基、C1-C4烷基取代的基基团或可由从由卤素原子、羟基和羧基组成的基团中选择的取代基团取代的C1-C4烷基,或其药学上可接受的盐。
  • Derivatives of 6-(2,3-dichlorophenyl)-1,2,4-triazin-5-amine
    申请人:Nektar Therapeutics
    公开号:US10189859B2
    公开(公告)日:2019-01-29
    The instant disclosure relates to (among other things) compounds that are derivatives of 6-(2,3-dichlorophenyl)-1,2,4-triazin-5-amine. The compounds provided possess unique effects and differences over other phenyltriazines known in the art.
    本公开涉及 6-(2,3-二氯苯基)-1,2,4-三嗪-5-胺衍生物的化合物。与本领域已知的其他苯基三嗪相比,所提供的化合物具有独特的效果和差异。
  • PYRROLOPYRIDAZINONE COMPOUND AS PDE4 INHIBITOR
    申请人:Ube Industries, Ltd.
    公开号:EP1982986B1
    公开(公告)日:2012-03-07
查看更多